Development and Validation of a New HPLC Method For the Detection of 5- Fluorouracil in Mobile Phase and in Plasma / Muhammad Hanif, Muhammad Faheem Akhtar, Shabana Naeem, Muqeet Wahid, Muhammad Ahmad Shehzad, Malik Saadullah, Bushra Nasir, Samina Afzal
Objective: To establish a particular, sensitive and accurate High Performance Liquid Chromatography (HPLC) technique for the specific and effective analysis of 5-Fluorouracil (5-FU) in mobile phase and in plasma. Method: Analytical methods for 5-FU in mobile phase and plasma were developed. An assay consisted of isocratic elution of 5-FU in prepacked column discovery R-HS C-18, 5micrometer, Catalog # 568523-U, column dimensions : 25cm x 4.6mm using mobile phase composed of 5 mmol/L potassium dihydrogen phosphate (pH 6.0) and methanol at a ratio of 96:4 v/v respectively. 5-FU was detected at 254 nm with the flow rate of 1 ml/min in both mobile phase and plasma. Results: Retention time was found to be 3.457 minutes in mobile phase and 2.543 minutes in plasma. System suitability test showed no robustness among the inter-day, intra-day analysis, mobile phase and column. Accuracy of the developed method proved reliability of the purposed procedure. %RSD analysis was found to be less than 2% and coefficient of correlation was found to be 1. Conclusion: Valuable precision, recovery and accuracy were observed indicating method reliability. Method can also be applicable for bioequivalence study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Current pharmaceutical analysis - 14(2018), 1, Seite 3- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hanif, Muhammad [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (5 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009051775 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009051775 | ||
| 003 | DE-627 | ||
| 005 | 20231128171230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009051775 | ||
| 035 | |a (KFL)prod_DARH_D0004PA.sgm.CAF5311DA17164A863EF007F75FBCF35A8A8F671 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Hanif, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and Validation of a New HPLC Method For the Detection of 5- Fluorouracil in Mobile Phase and in Plasma |c Muhammad Hanif, Muhammad Faheem Akhtar, Shabana Naeem, Muqeet Wahid, Muhammad Ahmad Shehzad, Malik Saadullah, Bushra Nasir, Samina Afzal |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (5 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: To establish a particular, sensitive and accurate High Performance Liquid Chromatography (HPLC) technique for the specific and effective analysis of 5-Fluorouracil (5-FU) in mobile phase and in plasma. Method: Analytical methods for 5-FU in mobile phase and plasma were developed. An assay consisted of isocratic elution of 5-FU in prepacked column discovery R-HS C-18, 5micrometer, Catalog # 568523-U, column dimensions : 25cm x 4.6mm using mobile phase composed of 5 mmol/L potassium dihydrogen phosphate (pH 6.0) and methanol at a ratio of 96:4 v/v respectively. 5-FU was detected at 254 nm with the flow rate of 1 ml/min in both mobile phase and plasma. Results: Retention time was found to be 3.457 minutes in mobile phase and 2.543 minutes in plasma. System suitability test showed no robustness among the inter-day, intra-day analysis, mobile phase and column. Accuracy of the developed method proved reliability of the purposed procedure. %RSD analysis was found to be less than 2% and coefficient of correlation was found to be 1. Conclusion: Valuable precision, recovery and accuracy were observed indicating method reliability. Method can also be applicable for bioequivalence study | ||
| 700 | 1 | |a Akhtar, Muhammad Faheem |e verfasserin |4 aut | |
| 700 | 1 | |a Naeem, Shabana |e verfasserin |4 aut | |
| 700 | 1 | |a Wahid, Muqeet |e verfasserin |4 aut | |
| 700 | 1 | |a Shehzad, Muhammad Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Saadullah, Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Nasir, Bushra |e verfasserin |4 aut | |
| 700 | 1 | |a Afzal, Samina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 14(2018), 1, Seite 3- |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2018 |g number:1 |g pages:3- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=14&issue=1&spage=3 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2018 |e 1 |h 3- | ||